

04 October 2022
ASX Code: MXC
LSE Code: MXC

Appointment of UK Advisor Hannam & Partners and Company Update

A
S
X

R
E
L
E
A
S
E

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based bio-pharma company specialising in the production and development of phytomedicines, is pleased to announce the formal appointment of UK capital markets advisor, Hannam & Partners, as financial and corporate advisors to the Company, with immediate effect (<https://www.hannam.partners/>).

Hannam & Partners are a highly regarded UK advisory firm with a long track record in UK capital markets, and more recently in the UK and EU cannabis sector.

The Board believes that this appointment, along with delivery on the commercial contracts and production plans currently in place, will greatly enhance the Company's ability to maximise its enterprise value for all shareholders in the future.

Appointment of new COO/Deputy CEO

The Company advises that it has appointed Ms Yifat Steuer as the Company's new Chief Operating Officer/Deputy CEO, with Ms Steuer having been previously engaged as an advisor to the executive team during 2022.

Ms Steuer has over 20 years of experience as an executive, working across a range of pharmaceutical companies including Johnson & Johnson and GlaxoSmithKline, as well as experience working with SMEs and start-ups.

Ms Steuer is a qualified Chartered Accountant and holds a MBA degree from Bayes Business School – University of London. Ms Steuer will work closely with CEO Roby Zomer to execute on MGC Pharma's business strategy, utilising her experience in pharmaceuticals, manufacturing, logistics, medical technology and digital health.

Chairman role change

The Company also advises that Mr Brett Mitchell's role as Chairman of the Company's board of directors has transitioned from an executive to a non-executive position, to be more in line with corporate structuring of UK listed companies. Mr Mitchell will continue to provide corporate and capital markets advisory services to the Company through an existing consultancy agreement between MGC and Mr Mitchell's private consulting company, as disclosed in the Company's recent 2022 Annual Report.

Investor Update – 11th October

Following the release of our 2022 Annual Report, the company is pleased to announce that it will be providing a live presentation via the Investor Meet Company platform on 11th Oct 2022 at 11:00am BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard, up until 9am the day before the meeting or at any time during the live presentation.

Investors can register with Investor Meet Company for free and add to meet MGC PHARMACEUTICALS LIMITED via:

<https://www.investormeetcompany.com/mgc-pharmaceuticals-limited/register-investor>

Investors who already follow MGC PHARMACEUTICALS LIMITED on the Investor Meet Company platform will automatically be invited to the presentation.

--Ends--

Authorised for release by the Executive Chairman, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer
CEO & Managing Director
+61 8 6382 3390
info@mgcpharma.com.au

MGC Pharmaceuticals Ltd

David Lim
Company Secretary
+61 8 6382 3390
info@mgcpharma.com.au

UK Financial and Corporate Advisor

Hannam & Partners

Rupert Fane / Nilesh Patel
+44 7810 056 104
rf@hannam.partners / nilesh@hannam.partners

UK Broker

Turner Pope

Andy Thacker
+44 203 657 0050
info@turnerpope.com

UK PR Advisors

Tavistock

Charles Vivian / Tim Pearson
+44 207 920 3150
mgcpharma@tavistock.co.uk

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels    